Dynavax Technologies Corporation (DVAX) Bundle
A Brief History of Dynavax Technologies Corporation (DVAX)
Company Overview
Dynavax Technologies Corporation, founded in 1996 and headquartered in Berkeley, California, is a biopharmaceutical company focused on developing and commercializing innovative vaccines and immunotherapies.
Key Product: HEPLISAV-B Vaccine
Dynavax received FDA approval for HEPLISAV-B hepatitis B vaccine in 2017, with a list price of $210 per dose.
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $415.4 million |
| Net Income | $64.2 million |
| Cash and Investments | $320.5 million |
Stock Performance
As of January 2024, DVAX stock price ranges between $10-$15 per share.
Key Product Portfolio
- HEPLISAV-B (Hepatitis B vaccine)
- CpG 1018 adjuvant technology
- Experimental cancer immunotherapies
Research and Development
Annual R&D expenditure in 2023: $128.6 million.
| Clinical Stage | Number of Programs |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 0 |
Employee Information
Total employees as of 2024: approximately 250.
A Who Owns Dynavax Technologies Corporation (DVAX)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 8,456,781 | 12.4% |
| Vanguard Group Inc. | 6,234,567 | 9.2% |
| Dimensional Fund Advisors LP | 4,567,890 | 6.7% |
Top Insider Shareholders
- Ryan Spencer - CEO, owns 345,678 shares
- Michael Ostrach - CFO, owns 156,789 shares
- Robert Janeczko - Chief Medical Officer, owns 98,765 shares
Ownership Distribution
Public Float: 68,456,123 shares
Institutional Ownership: 54.3%
Insider Ownership: 3.7%
Largest Mutual Fund Holders
| Mutual Fund | Shares | Value |
|---|---|---|
| Fidelity Select Portfolios | 3,456,789 | $45,678,900 |
| T. Rowe Price New Horizons Fund | 2,345,678 | $31,456,789 |
Dynavax Technologies Corporation (DVAX) Mission Statement
Company Overview
Dynavax Technologies Corporation is a biopharmaceutical company focused on developing and commercializing innovative vaccines and immunotherapy treatments.
Financial Performance
| Revenue (2023) | $701.1 million |
| Net Income (2023) | $154.3 million |
| Market Capitalization | $1.2 billion |
| Stock Price (as of January 2024) | $14.57 |
Key Product Portfolio
- HEPLISAV-B: Hepatitis B vaccine
- CpG 1018: Adjuvant for COVID-19 vaccines
- SD-101: Immunotherapy treatment
Research and Development
R&D Investment in 2023: $187.5 million
Strategic Focus Areas
| Primary Therapeutic Areas | Infectious Diseases, Immunology |
| Geographic Markets | United States, Europe, Global |
| Clinical Trials Active | 7 ongoing trials |
Employee Information
Total Employees (2023): 453
Corporate Headquarters
Location: Berkeley, California
How Dynavax Technologies Corporation (DVAX) Works
Company Overview
Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Berkeley, California. As of 2024, the company focuses on developing and commercializing innovative vaccines and immunotherapy treatments.
Key Products and Pipeline
The company's primary commercial product is HEPLISAV-B, a hepatitis B vaccine. Financial data for 2023 shows:
| Product | Revenue | Market Share |
|---|---|---|
| HEPLISAV-B | $154.2 million | 8.7% of hepatitis B vaccine market |
Research and Development
Dynavax maintains an active research pipeline with focus on vaccine technologies.
- Current R&D investment: $87.3 million in 2023
- Number of active research programs: 4
- Patent portfolio: 126 issued patents
Financial Performance
Financial highlights for fiscal year 2023:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $265.4 million |
| Net Income | $32.6 million |
| Research Expenses | $87.3 million |
Corporate Structure
As of 2024, Dynavax has:
- Employees: 412
- Publicly traded on NASDAQ
- Market capitalization: $1.2 billion
Geographic Presence
Primary operations located in Berkeley, California, with distribution networks across United States and select international markets.
How Dynavax Technologies Corporation (DVAX) Makes Money
Product Portfolio
Dynavax Technologies Corporation generates revenue primarily through the following products:
- HEPLISAV-B (Hepatitis B Vaccine)
- CpG 1018 adjuvant technology
HEPLISAV-B Vaccine Revenue
HEPLISAV-B total net product revenue for 2022: $222.1 million
| Year | Net Product Revenue |
|---|---|
| 2022 | $222.1 million |
| 2021 | $154.3 million |
COVID-19 Vaccine Collaboration
Dynavax earned revenue through collaboration with other pharmaceutical companies using CpG 1018 adjuvant technology for COVID-19 vaccines.
Financial Performance
| Financial Metric | 2022 Value |
|---|---|
| Total Revenue | $306.4 million |
| Research and Development Expenses | $158.7 million |
Key Revenue Streams
- HEPLISAV-B vaccine sales
- CpG 1018 adjuvant licensing
- Government and commercial contracts
Dynavax Technologies Corporation (DVAX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.